Inspire Medical Systems develops and commercializes an implantable hypoglossal nerve stimulation therapy for obstructive sleep apnea. The Inspire system is designed for patients with moderate to severe OSA who cannot tolerate or do not benefit from CPAP, placing the company in therapeutic sleep-related neuromodulation. FDA PMA materials describe Inspire Upper Airway Stimulation as a device for a defined subset of moderate to severe OSA patients.

The system stimulates the hypoglossal nerve during sleep to help maintain airway patency. Its implanted components include a pulse generator, stimulation lead, and respiratory sensing lead, with stimulation coordinated to breathing patterns. This gives Inspire a closed-loop device architecture built around peripheral nerve stimulation and respiratory sensing.

Inspire targets patients treated through sleep medicine and surgical care pathways, with implantation and follow-up handled by trained providers. The company is publicly listed and has an FDA PMA-approved therapy, placing it in a mature commercial category within implantable sleep neuromodulation. It is best understood as a specialized neuromodulation company focused on sleep-disordered breathing.